Ensysce Biosciences Inc. Common Stock ENSC · Stock Open Ensysce Biosciences Inc. Common Stock in new tab
Ensysce Biosciences Inc. Common Stock Analysis (ENSC)
Is Ensysce Biosciences Inc. Common Stock a good investment? Ensysce Biosciences Inc. Common Stock (ENSC) is currently trading at 0.4211 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.02. This relatively low multiple may signal that Ensysce Biosciences Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Ensysce Biosciences Inc. Common Stock is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.05.
Investor FAQ
Does Ensysce Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ensysce Biosciences Inc. Common Stock?
Ensysce Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -2.55.
Company Profile
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 28, 2022 | 1:20 |
| March 31, 2023 | 0.08 |
| Dec. 6, 2024 | 0.07 |
Community Discussion